The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Transfusions of red blood cells (RBCs) can be life-saving treatments for patients suffering from anemia, where the body lacks enough healthy RBCs to effectively deliver oxygen around the body. But the ...

In 2018, she suffered a stroke, a pulmonary embolism and a blood transfusion reaction as a ... It is an option for patients ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Sickle cell disease can be life ... and support they deserve." The therapy has already been approved for another inherited blood disorder, transfusion-dependent beta thalassemia.

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...